ATOS

Business Context and Reporting Period

Company: Atossa Therapeutics, Inc. (ATOS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Atossa is a clinical-stage biopharmaceutical company focused on oncology, specifically breast cancer, and rare diseases. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator/degrader currently in Phase 2 clinical development. The company has no commercial revenue and relies on capital raises to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by $9.3 million (36%) year-over-year, driven primarily by higher R&D and G&A expenses.
• R&D Expense Growth: R&D expenses rose 50% to $21.2 million, largely due to increased spending on clinical trials for (Z)-endoxifen and higher drug development costs.
• G&A Expense Growth: G&A expenses increased 18% to $16.0 million. This was driven by a $1.8 million increase in legal fees related to ongoing patent defense and litigation, partially offset by lower insurance premiums.
• Cash Burn: Cash and cash equivalents decreased by approximately $30 million during the year, reflecting the net loss and operating cash outflows.
• Stock Split: On February 2, 2026, the company effected a 1-for-15 reverse stock split to regain compliance with Nasdaq listing requirements regarding minimum bid price.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Capital Resources

Management expects existing resources ($41.3 million as of Dec 31, 2025) to fund planned operations for the next 12 months. However, the company has not established an ongoing source of revenue and has stated that substantial doubt exists regarding its ability to continue as a going concern without additional capital. A new "At the Market" offering agreement was entered into in February 2026 to raise up to $50 million.

Clinical Development Highlights

• Karisma Study: Top-line data on mammographic breast density reduction is expected in the first half of 2026. Initial data showed significant reduction at 1mg and 2mg doses.
• I-SPY 2 & EVANGELINE: Enrollment for combination therapy arms is nearly complete, with data expected in the second half of 2026.
• Rare Disease Designations: Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) in late 2025/early 2026.

Risks and Contingencies

• Going Concern: The company faces substantial doubt regarding its ability to continue operations beyond the next 12 months without further financing.
• Intellectual Property Litigation: Intas Pharmaceuticals Ltd. filed Post Grant Review (PGR) and Inter Partes Review (IPR) petitions in April 2025 seeking to invalidate two of Atossa's patents. Final decisions are expected by November 2026.
• Regulatory Compliance: The company previously failed to maintain Nasdaq minimum bid price requirements, necessitating a reverse stock split in February 2026.
• Tax Liability: The company recorded a liability of $1.1 million related to potential disqualification of Australian R&D tax rebates upon audit.

Key Facts for Investor Verification

• Liquidity Runway: Verify the sufficiency of the $41.3 million cash balance against the projected burn rate of ~$30 million annually.
• Patent Validity: Monitor the outcome of the Intas Pharmaceuticals PGR and IPR proceedings, which could invalidate core IP protecting (Z)-endoxifen.
• Clinical Data Readouts: Track the release of top-line data from the Karisma study (H1 2026) and I-SPY 2/EVANGELINE studies (H2 2026) for efficacy confirmation.
• Capital Raising: Assess the success of the new $50 million "At the Market" offering facility in securing necessary long-term funding.
• Reverse Stock Split Impact: Evaluate the post-split trading volume and price stability to ensure continued Nasdaq compliance.